Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > China Daily Article

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Nov 06, 2024 11:01am

87 Views

Post# 36298843

RE:RE:RE:RE:RE:China Daily Article

A buy out triggered by access to undisclosed positive results not available to the public
What an amateurish comment

mercedesman wrote:
Maybe...

...but I think the optics look bad if Spectral effectively goes off the market before at least the Top line data is released.

It would suggest ( give the appearance) that CG has access to info that the general market does not.

My guess is that the two events happen in fairly rapid succession. While other buyers would be well aware of the basement goldmine at top-line release, they would not have enough time to react with an offer.

Depends who's controlling the game ( Baxter, CG, Spectral or Toray )

JMO

MM